礼邦医药-B(09637.HK)：AP301胶囊治疗接受透析的慢性肾脏病患者高磷血症新药上市申请获国家药品监督管理局受理

智通财经08-07

【礼邦医药-B(09637.HK)：AP301胶囊治疗接受透析的慢性肾脏病患者高磷血症新药上市申请获国家药品监督管理局受理】智通财经APP讯，礼邦医药-B(09637.HK)发布公告，公司管线AP301胶囊(一款新型口服含铁磷结合剂)用于治疗接受维持性透析的慢性肾脏病患者高磷血症的新药上市申请，今日获中国国家药品监督管理局正式受理。该新药上市申请主要基于AP301在中国完成的关键III期临床试验 ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2657011619?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-08-07 17:26","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2657011619","market":"hk","top_or_hot":-1,"title":"礼邦医药-B(09637.HK)：AP301胶囊治疗接受透析的慢性肾脏病患者高磷血症新药上市申请获国家药品监督管理局受理","media":"智通财经","content":"<div>\n<p>【礼邦医药-B(09637.HK)：AP301胶囊治疗接受透析的慢性肾脏病患者高磷血症新药上市申请获国家药品监督管理局受理】智通财经APP讯，礼邦医药-B(09637.HK)发布公告，公司管线AP301胶囊(一款新型口服含铁磷结合剂)用于治疗接受维持性透析的慢性肾脏病患者高磷血症的新药上市申请，今日获中国国家药品监督管理局正式受理。该新药上市申请主要基于AP301在中国完成的关键III期临床试验 ...</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=ganggu\">网页链接</a>\n\n</div>\n","source":"live_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>礼邦医药-B(09637.HK)：AP301胶囊治疗接受透析的慢性肾脏病患者高磷血症新药上市申请获国家药品监督管理局受理</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n礼邦医药-B(09637.HK)：AP301胶囊治疗接受透析的慢性肾脏病患者高磷血症新药上市申请获国家药品监督管理局受理\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-07 17:26 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.zhitongcaijing.com/immediately.html?type=ganggu><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>【礼邦医药-B(09637.HK)：AP301胶囊治疗接受透析的慢性肾脏病患者高磷血症新药上市申请获国家药品监督管理局受理】智通财经APP讯，礼邦医药-B(09637.HK)发布公告，公司管线AP301胶囊(一款新型口服含铁磷结合剂)用于治疗接受维持性透析的慢性肾脏病患者高磷血症的新药上市申请，今日获中国国家药品监督管理局正式受理。该新药上市申请主要基于AP301在中国完成的关键III期临床试验 ...</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=ganggu\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","article_id":"2657011619","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2657011619","pubTimestamp":1786094817,"columns":[],"sourceInfo":{"source_id":"live_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"【礼邦医药-B(09637.HK)：AP301胶囊治疗接受透析的慢性肾脏病患者高磷血症新药上市申请获国家药品监督管理局受理】智通财经APP讯，礼邦医药-B(09637.HK)发布公告，公司管线AP30","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1191":"制药","BK1515":"抗疫概念","BK1161":"生物科技","09637":"礼邦医药-B","BK1574":"生物医药B类股","09939":"开拓药业-B"},"translate_title":"Li Bang Pharma-B (09637.HK): AP301 capsule for the treatment of hyperphosphatemia in patients with chronic kidney disease undergoing dialysis was accepted by the NMPA","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09939":1.5,"09637":1.5},"content_text":"【礼邦医药-B(09637.HK)：AP301胶囊治疗接受透析的慢性肾脏病患者高磷血症新药上市申请获国家药品监督管理局受理】智通财经APP讯，礼邦医药-B(09637.HK)发布公告，公司管线AP301胶囊(一款新型口服含铁磷结合剂)用于治疗接受维持性透析的慢性肾脏病患者高磷血症的新药上市申请，今日获中国国家药品监督管理局正式受理。该新药上市申请主要基于AP301在中国完成的关键III期临床试验 \n\nRESPOND-1的结果及其他累积临床资料。","kind":"live","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2657011619","isCrawlerRequest":true}